<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854970</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2012/08</org_study_id>
    <nct_id>NCT01854970</nct_id>
  </id_info>
  <brief_title>Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux</brief_title>
  <acronym>PHARO</acronym>
  <official_title>Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laryngopharyngeal reflux (LPR) is the retrograde movement of gastric contents into the
      larynx, pharynx and upper aerodigestive tract. The symptoms and manifestations are very
      changeable and non specific. Pharyngeal and Oesophageal pH-impedance may help to detect these
      reflux and to identify patients with abnormal LPR.

      To compare and describe the results of pharyngeal and oesophageal pH-impedance of patients
      with high suspicion of laryngopharyngeal reflux, with the results of healthy patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a monocentric, prospective descriptive study. Patients will be recruited in
      otolaryngology and gastroenterology departments of Bordeaux teaching hospital. A first
      clinical, endoscopic and pH-impedance evaluation will be made, after at least 15 days of
      interruption of any proton pump inhibitors (PPI). After 8 weeks' treatment by double PPI
      doses (esomeprazole 40 mg bid), another clinical and pH-impedance evaluation will be
      realized. The characteristics of the patients who respond to the treatment will be compared
      to non responders. The subjects will also have an initial laryngoscopy, an oesophageal
      manometry allowing the location of the lower sphincter of the oesophagus and the upper
      sphincter of the oesophagus for positioning the catheters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of pharyngeal reflux/24h</measure>
    <time_frame>visit 3 - 60 days after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• Number of pharyngeal acid reflux/24h</measure>
    <time_frame>Visit 3 - 60 days after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• Number of pharyngeal less acid reflux/24h</measure>
    <time_frame>Visit 3 - 60 days after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• Pharyngeal acid exposure (% of total time with pharyngeal pH &lt;4)</measure>
    <time_frame>Visit 3 - 60 days after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• Pharyngeal bolus exposure (% of total time with liquid in the pharynx)</measure>
    <time_frame>Visit 3 - 60 days after inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Laryngopharyngeal Reflux</condition>
  <condition>Oesophageal pH-impedance</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole</intervention_name>
    <description>Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age : 18 to 80 years old.

          -  Written consent

          -  Laryngopharyngeal symptoms (dysphonia, and/or globus and/or sensation, and/or
             pharyngeal pain, and/or cough) for 3 months at least.

          -  No PPI for at least 15 days

          -  Social security affiliation

        Exclusion Criteria:

          -  Sinusitis or chronic rhinitis (in the previous year)

          -  Laryngeal trauma, tracheotomy or pharyngolaryngeal surgery

          -  pregnancy or absence of efficacy contraception

          -  breast feeding

          -  history of gastrointestinal pathology, diabetes, neurological condition

          -  cardio-vascular history requiring the taking of Plavix

          -  esomeprazole contraindication or intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Laryngopharyngeal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

